What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

A vaccine against ALK-based resistance mutations induces immune responses against all of its targeted antigen in patients ...

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 ...

A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical ...

Seven-year analysis from Pfizer’s Lorbrena CROWN trial shows longest progression-free survival reported to date in advanced non-small cell lung cancer: New York Monday, June 1, ...

The Lung Cancer Research Foundation, in partnership with patients, survivors, caregivers, loved ones, industry partners and ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

Is Zykadia Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Zykadia is used for NSCLC that ...